Marinus Verwijs - 21 Mar 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Senior Vice President, CMC
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
21 Mar 2022
Net transactions value
$0
Form type
4
Filing time
23 Mar 2022, 07:47:34 UTC
Next filing
03 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +90,000 $0.000000 90,000 21 Mar 2022 Common Stock 90,000 $14.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments.